AU2008227100B2 - Pyridazinone derivatives useful as glucan synthase inhibitors - Google Patents

Pyridazinone derivatives useful as glucan synthase inhibitors Download PDF

Info

Publication number
AU2008227100B2
AU2008227100B2 AU2008227100A AU2008227100A AU2008227100B2 AU 2008227100 B2 AU2008227100 B2 AU 2008227100B2 AU 2008227100 A AU2008227100 A AU 2008227100A AU 2008227100 A AU2008227100 A AU 2008227100A AU 2008227100 B2 AU2008227100 B2 AU 2008227100B2
Authority
AU
Australia
Prior art keywords
compound
alkyl
candida
spp
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008227100A
Other languages
English (en)
Other versions
AU2008227100A1 (en
Inventor
Robert G. Aslanian
Jianhua Cao
Robert Jason Herr
David Won-Shik Kim
Rongze Kuang
Pauline C. Ting
Heping Wu
Jinhai Yang
Gang Zhou
Nicolas Zorn
Andrew John Zych
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Curia Global Inc
Original Assignee
Merck Sharp and Dohme Ltd
Albany Molecular Research Inc
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Albany Molecular Research Inc, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of AU2008227100A1 publication Critical patent/AU2008227100A1/en
Assigned to MERCK SHARP & DOHME CORP., ALBANY MOLECULAR RESEARCH, INC. reassignment MERCK SHARP & DOHME CORP. Alteration of Name(s) of Applicant(s) under S113 Assignors: ALBANY MOLECULAR RESEARCH, INC., SCHERING CORPORATION
Application granted granted Critical
Publication of AU2008227100B2 publication Critical patent/AU2008227100B2/en
Priority to AU2014201996A priority Critical patent/AU2014201996A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2008227100A 2007-03-15 2008-03-12 Pyridazinone derivatives useful as glucan synthase inhibitors Ceased AU2008227100B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2014201996A AU2014201996A1 (en) 2007-03-15 2014-04-08 Pyridazinone derivatives useful as glucan synthase inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91817107P 2007-03-15 2007-03-15
US60/918,171 2007-03-15
PCT/US2008/003257 WO2008115381A1 (en) 2007-03-15 2008-03-12 Pyridazinone derivatives useful as glucan synthase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2014201996A Division AU2014201996A1 (en) 2007-03-15 2014-04-08 Pyridazinone derivatives useful as glucan synthase inhibitors

Publications (2)

Publication Number Publication Date
AU2008227100A1 AU2008227100A1 (en) 2008-09-25
AU2008227100B2 true AU2008227100B2 (en) 2014-01-09

Family

ID=39525788

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008227100A Ceased AU2008227100B2 (en) 2007-03-15 2008-03-12 Pyridazinone derivatives useful as glucan synthase inhibitors

Country Status (18)

Country Link
US (1) US8232274B2 (enExample)
EP (2) EP2586778A3 (enExample)
JP (3) JP5147866B2 (enExample)
KR (1) KR20100049500A (enExample)
CN (1) CN101730692A (enExample)
AR (1) AR065721A1 (enExample)
AU (1) AU2008227100B2 (enExample)
BR (1) BRPI0809238A2 (enExample)
CA (1) CA2680583A1 (enExample)
CL (1) CL2008000725A1 (enExample)
CO (1) CO6220966A2 (enExample)
EC (1) ECSP099634A (enExample)
IL (1) IL200906A0 (enExample)
MX (1) MX2009009948A (enExample)
PE (1) PE20081882A1 (enExample)
RU (1) RU2009137946A (enExample)
TW (1) TW200902516A (enExample)
WO (1) WO2008115381A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2137162T3 (en) 2007-03-15 2018-11-26 Novartis Ag Organic compounds and their applications
EP2136808A2 (en) * 2007-03-15 2009-12-30 Schering Corporation Piperazine-substituted pyridazinone derivatives useful as glucan synthase inhibitors
MX2010003117A (es) * 2007-09-20 2010-04-01 Irm Llc Compuestos y composiciones como moduladores de la actividad de gpr119.
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
AU2011313906B2 (en) * 2010-10-11 2015-08-13 Axikin Pharmaceuticals, Inc. Salts of arylsulfonamide CCR3 antagonists
FI20115234A0 (fi) 2011-03-08 2011-03-08 Biotie Therapies Corp Uusia pyridatsinoni- ja pyridoniyhdisteitä
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
JO3115B1 (ar) * 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
AP2014007637A0 (en) 2011-11-15 2014-05-31 Takeda Pharmaceutical Dihydroxy aromatic heterocyclic compound
EP2836482B1 (en) * 2012-04-10 2019-12-25 The Regents of The University of California Compositions and methods for treating cancer
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
CN103664795B (zh) * 2012-09-06 2017-10-03 华东理工大学 哒嗪酮类化合物及其用途
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
WO2014053973A2 (en) 2012-10-05 2014-04-10 Koninklijke Philips N.V. Medical imaging system and method for providing an enhanced x-ray image
GB201222711D0 (en) 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
US10070649B2 (en) 2013-01-30 2018-09-11 Agrofresh Inc. Volatile applications against pathogens
WO2015031036A1 (en) * 2013-08-26 2015-03-05 Purdue Pharma L.P. Azaspiro[4.5] decane derivatives and use thereof
RU2692485C2 (ru) 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
CN106456708A (zh) * 2014-04-24 2017-02-22 赫希玛有限公司 治疗的试剂和方法
EP3426029B1 (en) 2016-03-07 2023-08-30 AgroFresh Inc. Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops
RU2019132396A (ru) * 2017-03-15 2021-04-15 Лунелла Байотек, Инк. Миторибосцины: терапевтические средства на основе митохондрий, направленные на раковые клетки, бактерии и патогенные дрожжи
BR112019020693B1 (pt) 2017-04-03 2023-11-28 Syngenta Participations Ag Compostos derivados de oxadiazol microbiocidas, suas composições, método para controlar ou prevenir a infestação de plantas úteis por microrganismos fitopatogênicos utilizando tais compostos e seus usos
EP3684364A4 (en) 2017-09-18 2021-06-02 Goldfinch Bio, Inc. PYRIDAZINONE AND METHOD OF USE THEREOF
CN109912476A (zh) * 2019-03-27 2019-06-21 南通宝凯化工有限公司 一种异丙氨基磺酰氯的生产工艺
WO2020253862A1 (zh) * 2019-06-21 2020-12-24 上海翰森生物医药科技有限公司 含氮芳基磷氧化物类衍生物、其制备方法和应用
WO2021113625A1 (en) * 2019-12-06 2021-06-10 Plexxikon Inc. Compounds and methods for cd73 modulation and indications therefor
WO2021222353A1 (en) 2020-04-30 2021-11-04 Gilead Sciences, Inc. Macrocyclic inhibitors of peptidylarginine deiminases
WO2023204124A1 (ja) * 2022-04-20 2023-10-26 日本曹達株式会社 ピリダジノン化合物並びに農園芸用殺菌剤、殺線虫剤、および医療用・動物用抗真菌剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04235975A (ja) * 1991-01-21 1992-08-25 Nissan Chem Ind Ltd ピリダジノン誘導体および害虫防除剤
CA2482151A1 (en) * 2002-04-12 2003-11-27 Bayer Healthcare Ag Substituted 2-phenyl-3(2h)-pyridazinones

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS565734B2 (enExample) * 1973-02-28 1981-02-06
DE3048487A1 (de) * 1980-12-22 1982-07-29 Cassella Ag, 6000 Frankfurt Basisch substituierte pyridazine, ihre herstellung und ihre verwendung
ES540813A0 (es) 1985-02-28 1985-11-16 Abello Quimicos Farma Prod Sa Procedimiento de obtencion de 1,2-diazin-3 (2h)-onas con interes farmaceutico
GB2256587A (en) 1991-06-11 1992-12-16 American Cyanamid Co Acetazolamide in sustained release form
HU227237B1 (en) * 2001-09-27 2010-12-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Substituted alkylpyridazinone derivatives, process for their preparation, pharmaceutical compositions containing them
CN1633434A (zh) * 2002-01-31 2005-06-29 第一制药株式会社 咪唑并[1,2－a]吡啶衍生物
US20050209278A1 (en) * 2002-04-25 2005-09-22 Mcdonald Joseph J Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
UA77526C2 (en) * 2002-06-07 2006-12-15 Sanofi Aventis Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy
JP4768628B2 (ja) * 2003-11-19 2011-09-07 アレイ バイオファーマ、インコーポレイテッド Ｍｅｋの二環系阻害剤及びその使用方法
AU2005249380C1 (en) * 2004-04-23 2012-09-20 Exelixis, Inc. Kinase modulators and methods of use
GB0524991D0 (en) * 2005-12-08 2006-01-18 Ge Healthcare Ltd Novel imaging agents for fibrosis
WO2007130383A2 (en) * 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
EP2136808A2 (en) * 2007-03-15 2009-12-30 Schering Corporation Piperazine-substituted pyridazinone derivatives useful as glucan synthase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04235975A (ja) * 1991-01-21 1992-08-25 Nissan Chem Ind Ltd ピリダジノン誘導体および害虫防除剤
CA2482151A1 (en) * 2002-04-12 2003-11-27 Bayer Healthcare Ag Substituted 2-phenyl-3(2h)-pyridazinones

Also Published As

Publication number Publication date
AU2008227100A1 (en) 2008-09-25
CA2680583A1 (en) 2008-09-25
EP2137179B1 (en) 2015-09-02
CO6220966A2 (es) 2010-11-19
CN101730692A (zh) 2010-06-09
MX2009009948A (es) 2009-09-24
KR20100049500A (ko) 2010-05-12
US8232274B2 (en) 2012-07-31
JP2013014622A (ja) 2013-01-24
PE20081882A1 (es) 2008-12-27
ECSP099634A (es) 2009-10-30
EP2586778A3 (en) 2013-07-31
WO2008115381A1 (en) 2008-09-25
IL200906A0 (en) 2010-05-17
CL2008000725A1 (es) 2008-11-14
AR065721A1 (es) 2009-06-24
EP2586778A2 (en) 2013-05-01
JP5147866B2 (ja) 2013-02-20
JP2014051529A (ja) 2014-03-20
JP2010521461A (ja) 2010-06-24
BRPI0809238A2 (pt) 2014-09-09
TW200902516A (en) 2009-01-16
US20090170861A1 (en) 2009-07-02
EP2137179A1 (en) 2009-12-30
RU2009137946A (ru) 2011-04-20

Similar Documents

Publication Publication Date Title
AU2008227100B2 (en) Pyridazinone derivatives useful as glucan synthase inhibitors
EP3402799B1 (en) Heterocyclic compounds as rsv inhibitors
US8022088B2 (en) Substituted bicyclic and tricyclic thrombin receptor antagonists
EP2217611B1 (en) Novel modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
EP3129380B1 (en) Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one derivatives and their use as mdm2-p53 inhibitors
EP2819996B1 (en) 6-alkynyl pyridines as smac mimetics
CA3071143A1 (en) Novel compounds
CA2680587A1 (en) Piperazine-substituted pyridazinone derivatives useful as glucan synthase inhibitors
US20070232635A1 (en) Monocyclic and bicyclic himbacine derivatives useful as thrombin receptor antagonists
CN107001385A (zh) 作为mdm2‑p53抑制剂的新的螺‑[3h‑吲哚‑3，2’‑吡咯烷]‑2(1h)‑酮化合物及其衍生物
CA3000063A1 (en) Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
AU2007269836A1 (en) Substituted piperidines that increase P53 activity and the uses thereof
JP2010533716A (ja) プロテインキナーゼ阻害剤としての複素環アミド化合物
JP2013532652A (ja) 新規アミノピラゾロキナゾリン
KR20110033239A (ko) 단백질 키나제 억제제
WO2009097233A9 (en) Imidazopyrazines as protein kinase inhibitors
CN116348469A (zh) 一种高活性Wnt通路抑制剂化合物
EP3157922B1 (en) Pyrazolo-pyridine derivatives as kinase inhibitors
AU2020413555B2 (en) PD-L1 antagonist compound
WO2007075809A2 (en) Oxazoloisoquinoline derivatives as thrombin receptor antagonists
AU2014201996A1 (en) Pyridazinone derivatives useful as glucan synthase inhibitors
HK30089209A2 (en) Hpk1 kinase inhibitor compound
HK30089210A2 (en) A highly active wnt pathway inhibitor compound
AU2006302435A1 (en) Use of pyrazolo [1 , 5 -a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases
TW201307315A (zh) 作為絲胺酸／蘇胺酸激酶抑制劑之新穎三唑基苯基磺醯胺

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired